Bülent ÇELİK, Serdar KULA, Vildan ATASAYAN, Fatma CANBEYLİ, Fatma Sedef TUNAOGLU, Ayse Deniz OĞUZ

Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension

Background/aim: To evaluate the pre and post-treatment heart rate and oxygen (O2 ) saturation values measured before, during and after 6MWT in children who received PAH-specific treatment and to determine the effect of these variables on prognosis. Materials and methods: This retrospective study included 29 patients who were diagnosed as PAH and treated. The transcutaneous O2 saturationand heart rate levels were recorded before the test: baseline (Sat0, HR0), at the end of the test: exercise (Sat1,HR1) and 5 min after the test: recovery (Sat2, HR2). The increase in heart rate was defined as HR1-HR0 and the decrease in saturation as Sat0-Sat1. The results obtained before and after the PAH-specific treatment were analyzed and their effect on survival was assessed. Results: Fifteen of 29 patients were female (51.7%). The mean age was 127.2 ± 44.8 months and the median follow-up time was 60 (12–156) months. Only pre-treatment HR1 was found associated with survival. The mean HR1 value of survivors was 122.8 ± 18.4 and that of deceased 94.3 ± 19.1 (p = 0.03). Post-treatment 6MWT was associated with survival. It was 453.3 ± 96.5 m for survivors and 250 ± 135.2 m for deceased (p = 0.02). Conclusion: Post-treatment 6MWT, FC and proBNP had prognostic value in pediatric patients with PAH. The decrease in saturation and increase in heart rate were not found to have a prognostic value. Pre-treatment HR1 was associated with survival. Identification of these prognostic factors at the beginning and throughout the treatment may be a guide for detecting the severity of the disease and follow-up.Key words: 6-minute walk test, pulmonary arterial hypertension, survival, heart rate

PDF

___

1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal 2015; 46: 903-975. doi: 10.1093/eurheartj/ehv317
2. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132: 2037-2099. doi: 10.1161/ CIR.0000000000000329
3. Hansmann G, Apitz C, Abdul- Khaliq H, Alastalo TP, Beerbaum P et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The european paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart 2016; 102 (2): 86-100. doi: 10.1136/heartjnl-2015-309132
4. Kula S, Pektaş A. A review of pediatric pulmonary hypertension with new guidelines. Turkish Journal of Medical Sciences 2017; 47 (2): 375-380. doi: 10.3906/sag-1605-172
5. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122: 164-172. doi: 10.1161/CIRCULATIONAHA.109.898122
6. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2000; 161: 487-492. doi: 10.1164/ajrccm.161.2.9906015
7. Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D et al. Pediatric pulmonary hypertension. Journal of American College of Cardiology 2013; 62 (25): 117-126. doi: 10.1016/j. jacc.2013.10.028
8. Moledina S, Pandya B, Bartsota M, Mortensen KH, McMillan M et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Circulation Cardiovascular Imaging 2013; 6 (3): 407-414. doi: 10.1161/ CIRCIMAGING.112.000082
9. Wagner BD, Takatsuki S, Accurso FJ, Ivy DD. Evaluation of circulating proteins and hemodynamics towards predicting mortality in children with pulmonary arterial hypertension. PLoS One 2013; 8 (11): 80235. doi: 10.1371/journal. pone.0080235
10. Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. International Journal of Cardiology 2010; 142 (2): 159-165. doi: 10.1016/j.ijcard.2008.12.087
11. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125: 113-122. doi: 10.1161/CIRCULATIONAHA.111.026591
12. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406. doi: 10.1136/ hrt.2009.182378
13. Ramos RP, Arakaki JS, Barbosa P, Treptow E, Valois FM et al. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. American Heart Journal 2012; 163: 580-588. doi: 10.1016/j. ahj.2012.01.023
14. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. European Respiratory Journal 2001; 17: 647-652. doi: 10.1183/09031936.01.17406470
15. Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K et al. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2012; 185: 400-408. doi: 10.1164/rccm.201105-0848OC
16. Douwes JM, Hegemanb AK, Van der Krieke MB, Roofthooft MTR, Hillege HL et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. International Journal of Cardiology 2016; 202: 34-39. doi: 10.1016/j. ijcard.2015.08.155
17. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D et al. Definitions and diagnosis of pulmonary hypertension. Journal of American College of Cardiology 2013; 62 (25): 42- 50. doi: 10.1016/j.jacc.2013.10.032
18. ATS committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002; 166: 111-117. doi: 10.1164/ ajrccm.166.1.at1102
19. Zuk M, Migdal A, Jagiellowicz-Kowalska D, Mazurkiewicz K, Sadel-Wieczorek A et al. Six-minute walk test in evaluation of children with pulmonary arterial hypertension. Pediatric Cardiology 2017; 38: 754-761. doi: 10.1007/s00246-017-1575-z
20. Van Loon RL, Roofthooft MT, Delhaas T, Van Osch-Gevers M, Ten Harkel AD et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. American Journal of Cardiology 2010; 106: 117-124. doi: 10.1016/j.amjcard.2010.02.023
21. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. European Respiratory Journal 2014; 44: 1616-1626. doi: 10.1183/09031936.00030414
22. Lammers AE, Diller GP, Odendaal D, Tailor S, Derrick G et al. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Archives of Disease in Childhood 2011; 96: 141- 147. doi: 10.1136/adc.2009.169904
23. Paolillo S, Farina S, Bussotti M, Iorio A, PerroneFilardi P et al. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. European Journal of Preventive Cardiology 2012; 19: 960-971. doi: 10.1177/1741826711426635
24. Ploegstra MJ, Zijlstra WM, Douwes JM, Hillege HL, Berger RM. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. International Journal of Cardiology 2015; 184: 198-207. doi: 10.1016/j.ijcard.2015.01.038
25. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a doubleblind, randomised controlled trial. Lancet 2008; 371 (9630): 2093-2100. doi: 10.1016/S0140-6736(08)60919-8
26. Fraisse A, Jais X, Schleich JM, Filippo SD, Maragnès P et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Archives of Cardiovascular Diseases 2010; 103 (2): 66-74. doi: 10.1016/j. acvd.2009.12.001
27. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. European Respiratory Journal 2011; 38 (1): 70-77. doi: 10.1183/09031936.00053510